RecruitingPhase 2NCT03363373
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Studying Ependymoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Y-mAbs Therapeutics
- Intervention
- GM-CSF + Naxitamab(biological)
- Enrollment
- 122 target
- Eligibility
- 1 years · All sexes
- Timeline
- 2018 – 2028
Study locations (26)
- University of Florida, Gainesville, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- M.D. Anderson Cancer Center, Houston, Texas, United States
- The Hospital for Sick Children, Toronto, Canada
- Rigshospitalet, Copenhagen, Denmark
- Hopital pour enfants de la Timone, Marseille, Marseille, France
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Johannes Gutenberg-Universität, Mainz, Germany
- University Hospital Regensburg, Regensburg, Germany
- Hong Kong Children's Hospital, Hong Kong, Hong Kong
- Queen Mary Hospital, Hong Kong, Hong Kong
- Tata Memorial Centre, Mumbai, India
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03363373 on ClinicalTrials.govOther trials for Ependymoblastoma
Additional recruiting or active studies for the same condition.